Noxopharm Ltd
NOX
Company Profile
Business description
Noxopharm Ltd is an Australian clinical-stage drug development company focused on discovering and developing novel treatments for cancer and inflammation, as well as improving mRNA vaccines, based on two preclinical platforms. It is engaged in one segment which is the clinical development in the field of both oncology and non-oncology in the pan-pacific region.
Contact
60 Linksley Avenue
GlenhavenNSW2156
AUSSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
17
Stocks News & Analysis
stocks
Investors overlooking ASX share’s potential
International expansion is a distraction from valuable local business.
stocks
Cerebras sees blockbuster demand, setting stage for US AI IPO frenzy
The chipmaker’s IPO priced at $185, well above its initial range, and opened trading at an eye-popping $350.
stocks
What did Morningstar subscribers buy and sell in April?
How the most traded shares in April stack up against our analysts views.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,880.40 | 36.90 | -0.41% |
| CAC 40 | 8,082.27 | 0.00 | 0.00% |
| DAX 40 | 24,456.26 | 319.45 | 1.32% |
| Dow JONES (US) | 50,063.46 | 370.26 | 0.75% |
| FTSE 100 | 10,372.93 | 47.58 | 0.46% |
| HKSE | 26,155.33 | 233.71 | -0.89% |
| NASDAQ | 26,635.22 | 232.88 | 0.88% |
| Nikkei 225 | 62,141.93 | 512.12 | -0.82% |
| NZX 50 Index | 12,951.78 | 73.29 | -0.56% |
| S&P 500 | 7,501.24 | 56.99 | 0.77% |
| S&P/ASX 200 | 8,637.50 | 36.00 | -0.42% |
| SSE Composite Index | 4,144.33 | 33.58 | -0.80% |